Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands

• US 5,714,142 A
• Filed: 06/13/1996
• Issued: 02/03/1998
• Est. Priority Date: 02/23/1994
• Status: Expired due to Fees

• Current Assignee: Blaney, Jeffrey M., Cohen, Fred
• Original Assignee: Blaney, Jeffrey M., Cohen, Fred
• Inventors: Cohen, Fred, Blaney, Jeffrey M.
• Primary Examiner(s): CLARDY, S
• Application Number:
  US08/664,372
• Time in Patent Office: 600 Days
• Field of Search: 424/85.2, 424/85.4, 514/776, 514/772, 514/11, 514/16, 514/262, 514/274, 514/335, 514/368, 514/421, 514/423, 514/460, 514/471, 514/567, 514/568, 514/571, 514/620, 514/626, 514/737
• US Class Current: 424/85.2
• CPC Class Codes: A61K 47/54 the modifying agent being an organic compound
• CPC Class Codes: A61K 47/545 Heterocyclic compounds A61K47/558 takes precedence

Abstract

Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.

Claims

1. A pharmaceutical composition comprising a covalent conjugate of a pharmacologically active agent and a transthyretin-selective ligand whose binding affinities for thyroid-binding globulin and thyroid hormone receptor are each less than about 1% that of the binding affinity of said ligand for transthyretin, wherein the transthyretin-selective ligand is selected from the group consisting of the following structural formulae (l), (II) and (IV):

##STR25## wherein;

n is 0 or 1;

X is NH, O or lower alkylene optionally substituted with 1 to 4 substituents selected from the group consisting of lower alkyl, hydroxyl, carboxyl, halogen, amino, lower alkyl-substituted secondary amino, and lower alkyl-disubstituted tertiary amino and, if lower alkylene, optionally containing 1 to 4 --O--, --NH--, --CONH-- or --(CO)-- linkages;

R¹, R², R³, R⁴, R⁵, R⁶, and R¹¹ are selected from the group consisting of hydrogen, halogen, halogen-substituted lower alkyl, hydroxyl, lower alkyl, cyano, --(CH₂)_m CHO, --(CH₂)_m OH, --(CH₂)_m COOR¹³, and --(CH₂)_m CONHR¹⁴ wherein m is 0 or 1, R¹³ is hydrogen or C₁ -C₁₂ alkyl, C₁ -C₁₂ alkenyl or C₁ -C₁₂ alkynyl, and, when R¹³ is other than hydrogen, it is optionally substituted with 1 to 8 substituents selected from the group consisting of hydroxyl, carboxyl, lower alkyl, halogen and amino, and further optionally contains 1 to 8 --O--, --NH--, or --(CO)-- linkages, and R¹⁴ is hydrogen or lower alkyl, with the proviso that at least one of R¹, R² and R³, and at least one of R⁴, R⁵ and R⁶ is hydroxyl or --(CH₂)_m COOH; and

R¹² is hydrogen or lower alkyl.

2. The pharmaceutical composition of claim 1, wherein the pharmacologically active agent is selected such that following administration to a mammalian individual, at least about 50% of the agent is cleared through urinary excretion and less than 10% of the agent is metabolized or actively transported.

3. The pharmaceutical composition of claim 2, wherein the pharmacologically active agent is further selected such that following administration to a mammalian individual, the plasma binding of the drug is less than about 50%.

4. The pharmaceutical composition of claim 1, wherein the transthyretin-selective ligand has the structural formula (I).

5. The pharmaceutical composition of claim 1, wherein the transthyretin-selective ligand is tetraiodothyroacetic acid.

6. The pharmaceutical composition of claim 4, wherein the transthyretin-selective ligand is flufenamic acid.

7. The pharmaceutical composition of claim 4, wherein the transthyretin-selective ligand is diflunisal.

8. The pharmaceutical composition of claim 1, wherein the transthyretin-selective ligand has the structural formula (II).

9. The pharmaceutical composition of claim 8, wherein the transthyretin-selective ligand is milrinone.

10. The pharmaceutical composition of claim 1, wherein the transthyretin-selective ligand has the structural formula (IV).

11. The pharmaceutical composition of claim 10, wherein the transthyretin-selective ligand is EMD 21388.

12. The pharmaceutical composition of claim 1, wherein the pharmacologically active agent is a peptide drug or a fragment thereof.

13. The pharmaceutical composition of claim 1, wherein the pharmacologically active agent is selected from the group consisting of acyclovir, amoxicillin, ampicillin, arginine vasopressin, azlocillin, captopril, carbenicillin, ceflacor, cefadroxil, cefamandole, cephaloxin, cilastatin, cimetidine, dideoxyinosine, d4T, endothelin, famotidine, imipenem, insulin, β

-interferon interleukin-2, lidocaine, nizatidine, octreotide, procainamide, N-acetyl-procainamide, ranitidine, nizatidine, saralasin, superoxide dismutase, ticarcillin and zidovudine.

14. A method for extending the half-life of a pharmacologically active agent containing a functional group not essential for pharmacological activity, comprising covalently binding said agent, through said functional group, to a transthyretin-selective ligand whose binding affinities for thyroid-binding globulin and thyroid hormone receptor are each less than about 1% that of the binding affinity of said ligand for transthyretin.

15. The method of claim 14, wherein the transthyretin-selective ligand is selected from the group consisting of the following structural formulae (I) through (IV):

##STR26## wherein;

n if 0 or 1;

X is NH, O or lower alkylene optionally substituted with 1 to 4 substituents selected from the group consisting of lower alkyl, hydroxyl, carboxyl, halogen, amino, lower alkyl-substituted secondary amino, and lower alkyl-disubstituted tertiary amino and, if lower alkylene, optionally containing 1 to 4 --O--, --NH--, --CONH-- or --(CO)-- linkages;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are selected from the group consisting of hydrogen, halogen, halogen-substituted lower alkyl, hydroxyl, lower alkyl, cyano, --(CH₂)_m CHO, --(CH₂)_m OH, --(CH₂)_m COOR¹³, and --(CH₂)_m CONHR¹⁴ where m is 0 or 1, R¹³ is hydrogen or C₁ -C₁₂ alkyl, C₁ -C₁₂ alkenyl or C₁ -C₁₂ alkynyl and, when R¹³ is other than hydrogen, it is optionally substituted with 1 to 8 substituents selected from the group consisting of hydroxyl, carboxyl, lower alkyl, halogen and amino, and optionally containing 1 to 8 --O--, --NH-- or --(CO)-- linkages, and R¹⁴ is hydrogen or lower alkyl, with the proviso that at least one of R¹, R² and R³, at least one of R⁴, R⁵ and R⁶, and at least one of R⁷, R⁸, R⁹ and R¹⁰ is hydroxyl or --(CH₂)_m COOH; and

R¹² is hydrogen or lower alkyl.

16. The method of claim 15, wherein the transthyretin-selective ligand has the structural formula (I).

17. The method of claim 16, wherein the transthyretin-selective ligand is tetraiodothyroacetic acid.

18. The method of claim 16, wherein the transthyretin-selective ligand is flufenamic acid.

19. The method of claim 16, wherein the transthyretin-selective ligand is diflunisal.

20. The method of claim 15, wherein the transthyretin-selective ligand has the structural formula (II).

21. The method of claim 20, wherein the transthyretin-selective ligand is milrinone.

22. The method of claim 15, wherein the transthyretin-selective ligand has the structural formula (III).

23. The method of claim 22, wherein the transthyretin-selective ligand is 2,4,6-triiodophenol.

24. The method of claim 15, wherein the transthyretin-selective ligand has the structural formula (IV).

25. The method of claim 24, wherein the transthyretin-selective ligand is EMD 21388.

26. The method of claim 14, wherein the pharmacologically active agent is a peptide drug or a fragment thereof.

27. The method of claim 14, wherein the pharmacologically active agent is selected from the group consisting of acyclovir, amoxicillin, ampicillin, arginine vasopressin, azlocillin, captopril, carbenicillin, ceflacor, cefadroxil, cefamandole, cephaloxin, cilstatin, cimetidine, dideoxyinosine, d4T, endothelin, famotidine, imipenem, insulin, β

-interferon interleukin-2, lidocaine, nizatidine, octreotide, procainamide, N-acetyl-procalnamide, ranitidine, nizatidine, saralasin, superoxide dismutase, ticarcillin and zidovudine.